.Attributes Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for introduction of people along with MASLD and dimension of liver outcomes in cardio-- kidney-- metabolic trials, when data propose mechanistically plausible benefits and medical security-- as well as summarizes points to consider for trial concept and also regulatory approval.